178 related articles for article (PubMed ID: 27268052)
1. Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.
Beck D; Zobel J; Barber R; Evans S; Lezina L; Allchin RL; Blades M; Elliott R; Lord CJ; Ashworth A; Porter AC; Wagner SD
J Biol Chem; 2016 Aug; 291(32):16686-98. PubMed ID: 27268052
[TBL] [Abstract][Full Text] [Related]
2. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.
Hao Y; Chapuy B; Monti S; Sun HH; Rodig SJ; Shipp MA
Clin Cancer Res; 2014 May; 20(10):2674-83. PubMed ID: 24610827
[TBL] [Abstract][Full Text] [Related]
3. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
[TBL] [Abstract][Full Text] [Related]
4. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
5. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
6. A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway.
Lu K; Li B; Zhang H; Xu Z; Song D; Gao L; Sun H; Li L; Wang Y; Feng Q; Chen G; Hu L; Wei R; Xie Y; Yu D; Wu X; Zhu W; Shi J
Signal Transduct Target Ther; 2020 Apr; 5(1):31. PubMed ID: 32296013
[TBL] [Abstract][Full Text] [Related]
7. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
[TBL] [Abstract][Full Text] [Related]
8. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
Hu G; Witzig TE; Gupta M
PLoS One; 2013; 8(7):e67851. PubMed ID: 23861822
[TBL] [Abstract][Full Text] [Related]
9. Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.
Alsharif R; Dunleavy K
Hematol Oncol Clin North Am; 2019 Aug; 33(4):587-596. PubMed ID: 31229156
[TBL] [Abstract][Full Text] [Related]
10. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
12. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
13. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
14. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
[TBL] [Abstract][Full Text] [Related]
15. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
16. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
18. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
19. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.
Gupta M; Han JJ; Stenson M; Maurer M; Wellik L; Hu G; Ziesmer S; Dogan A; Witzig TE
Blood; 2012 Mar; 119(12):2844-53. PubMed ID: 22323454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
